What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
Comprehensive insights on the unmet needs addressed by TAR-200 in BCG-unresponsive non-muscle-invasive bladder cancer.
EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC
EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
EP: 4.Ongoing Research in BCG-Unresponsive NMIBC
EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
EP: 6.Emerging Agents in BCG-Unresponsive NMIBC
EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
Shore discusses advantages of the TAR-200 drug delivery device for treating high-risk non–muscle invasive bladder cancer (NMIBC). The device is user friendly for physicians and patients and similar in complexity to placing a urinary catheter. As a sustained-release platform, TAR-200 avoids challenges with standard intravesical chemotherapy related to bladder capacity and retention. The current TAR-200 formulation delivers gemcitabine, known to have antitumor effects based on intravesical and systemic chemotherapy studies. Other drugs like erdafitinib are being tested (TAR-210).
If 1- to 2-year durability is proven, TAR-200 could help patients avoid cystectomy, which is preferable given morbidity and life impact. For high-risk NMIBC, the goal remains preventing progression to more advanced disease in a window where micrometastatic spread may occur.
Video synopsis is AI generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
